EPO and Hypertension: The underlying molecular mechanisms are incompletely understood, but may involve atherosclerosis, vascular dysfunction, hypertension, type 2 diabetes, history of cardiac disease, and total homocysteine, and possibly, lack of erythropoietin formation by the kidney.